Funny I thought Sanofi prefers soft launches. I guess that's just for other company's products. But for their own they advertise everywhere. By the way, the reason that the stock went to 4 and then back up was short coverings. It will go back down when next round of sales are announced.
Afrezza's second-quarter sales came in at a meager $2.2 million for the three month period and $3.3 million for the entire first half of the year--putting it well off of the track toward blockbuster status.
Sales of MannKind's (MNKD) inhaled insulin Afrezza totaled #$%$2 million in the second quarter, as reported Thursday by marketing partner Sanofi (SNY - Get Report).
Whether you prefer sales reported in euros or converted into dollars ($2.2 million), Afrezza's performance in the first full quarter of its commercial launch was poor. The only saving grace is that no one, not even the most Kool-Aid-drinking MannKind supporter, is surprised.